PTGX
$97.23
Protagonist Therapeutics, Inc.
Intraday
Recent News
FDA Grants Priority Review for Takeda (TAK) and Protagonist’s Rusfertide in PV Treatment
Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the most promising stocks under $20. On March 2, Takeda and Protagonist Therapeutics announced that the US FDA accepted the New Drug Application and granted Priority Review for rusfertide. This investigational, first-in-class hepcidin mimetic is intended to treat adults with polycythemia vera/PV, a rare blood cancer characterized […]
Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift
Protagonist Therapeutics recently reported fourth-quarter and full-year 2025 results showing a shift from prior-year profitability to a net loss of US$44.38 million for the quarter and US$130.15 million for the year, alongside weaker per-share performance. At the same time, the company advanced its pipeline by submitting a New Drug Application for rusfertide, outlining plans to alter its collaboration economics with Takeda, and signaling an upcoming U.S. regulatory decision for ICOTYDE in...
Protagonist Therapeutics: Q4 Earnings Snapshot
NEWARK, Calif. AP) — Protagonist Therapeutics Inc. PTGX) on Wednesday reported a loss of $44.4 million in its fourth quarter.
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit
This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance.